Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis

• Published in: PloS one
• Main Authors: Llufriu Duran, Sara, Sepúlveda, María, Blanco, Yolanda, Marín, Pedro, Moreno, Beatriz, Berenguer, Joan, Gabilondo, Iñigo, Martínez Heras, Eloy, Sola Valls, Nuria, Arnaiz Gargallo, Juan Alberto, Andreu, Enrique J, Fernández, Begoña, Bullich Roig, Santiago, Sánchez Dalmau, Bernardo, Graus Ribas, Francesc, Villoslada, Pablo, Saiz Hinajeros, Albert
• Format: Journal Article
• Language: English
• Published: Public Library of Science (PLoS) 01-12-2014
• Subjects: Assaigs clínics; B cells; Clinical trials; Cèl·lules B; Cèl·lules mare; Cèl·lules T; Esclerosi múltiple; Magnetic resonance; Multiple sclerosis; Ressonància magnètica; Stem cells; T cells
• ISSN: 1932-6203; 1932-6203

OBJECTIVE: Uncontrolled studies of mesenchymal stem cells (MSCs) in multiple sclerosis suggested some beneficial effect. In this randomized, double-blind, placebo-controlled, crossover phase II study we investigated their safety and efficacy in relapsing-remitting multiple sclerosis patients. Efficacy was evaluated in terms of cumulative number of gadolinium-enhancing lesions (GEL) on magnetic resonance imaging (MRI) at 6 months and at the end of the study. METHODS: Patients unresponsive to conventional therapy, defined by at least 1 relapse and/or GEL on MRI scan in past 12 months, disease duration 2 to 10 years and Expanded Disability Status Scale (EDSS) 3.0-6.5 were randomized to receive IV 1-2×10(6) bone-marrow-derived-MSCs/Kg or placebo. After 6 months, the treatment was reversed and patients were followed-up for another 6 months. Secondary endpoints were clinical outcomes (relapses and disability by EDSS and MS Functional Composite), and several brain MRI and optical coherence tomography measures. Immunological tests were explored to assess the immunomodulatory effects. RESULTS: At baseline 9 patients were randomized to receive MSCs (n = 5) or placebo (n = 4). One patient on placebo withdrew after having 3 relapses in the first 5 months. We did not identify any serious adverse events. At 6 months, patients treated with MSCs had a trend to lower mean cumulative number of GEL (3.1, 95% CI = 1.1-8.8 vs 12.3, 95% CI = 4.4-34.5, p = 0.064), and at the end of study to reduced mean GEL (-2.8±5.9 vs 3±5.4, p = 0.075). No significant treatment differences were detected in the secondary endpoints. We observed a non-significant decrease of the frequency of Th1 (CD4+ IFN-γ+) cells in blood of MSCs treated patients. CONCLUSION: Bone-marrow-MSCs are safe and may reduce inflammatory MRI parameters supporting their immunomodulatory properties. ClinicalTrials.gov NCT01228266.